| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Federal grants | 493,104 | 1,371,438 | 1,319,772 | 3,418,853 |
| Research and development | 2,954,909 | 1,923,430 | 1,885,528 | 1,690,674 |
| General and administrative | 1,279,290 | 1,198,523 | 1,401,756 | 1,083,433 |
| Total operating expenses | 4,234,199 | 3,121,953 | 3,287,284 | 2,774,107 |
| Income (loss) from operations | -3,741,095 | -1,750,515 | -1,967,512 | 644,746 |
| Change in fair value of liability classified warrants | 998 | -853 | 9,916 | 6,403 |
| Interest expense, net | 6,369 | 3,160 | 3,856 | 4,063 |
| Other income and expense, net | 17,338 | 21,011 | 15,879 | 14,683 |
| Total other income (expense), net | 11,967 | 16,998 | 21,939 | 17,023 |
| Net income (loss) | -3,729,128 | -1,733,517 | -1,945,573 | 661,769 |
| Deemed dividend related to warrants down round provision | - | 0 | - | - |
| Net loss attributable to noncontrolling interests | - | -166 | - | - |
| Net income (loss) attributable to common stockholders | -3,729,128 | -1,733,351 | -1,945,573 | 661,769 |
| Net income (loss) per share attributable to common stockholders, basic | -1.29 | -0.79 | -1.39 | 0.07 |
| Net income (loss) per share attributable to common stockholders, diluted | -1.29 | -0.79 | -1.39 | 0.07 |
| Weighted average common shares outstanding, basic | 2,886,059 | 2,202,299 | 1,401,144 | 9,890,390 |
| Weighted average common shares outstanding, diluted | 2,886,059 | 2,202,299 | 1,401,144 | 9,890,390 |
Ensysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc. (ENSC)